ABI
DVA icon

Adamant Biomedical Investments’s DaVita DVA Stock Holding History

Adamant Biomedical Investments’s Portfolio DVA Stock Details DVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.97M Hold
26,000
– – 0.47% 65
2014
Q3 		$1.9M Buy
+26,000
New +$1.9M 0.47% 60

Other funds holding DVA

Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ECU
Egerton Capital (UK) London, United Kingdom $10.4B AUM 25.66% 1-Year Est. Return

Adamant Biomedical Investments's DVA Position: Q4 2014 in Review

Adamant Biomedical Investments held its DaVita (DVA) position steady in Q4 2014 at 26,000 shares worth $1.97M. The position accounts for 0.47% of the portfolio, ranked #65.

Adamant Biomedical Investments first reported a position in DVA in Q3 2014 and has held it in 2 quarters since. 495 funds tracked by Wall St. Rank hold DVA as of Q4 2014.

  • Adamant Biomedical Investments held 26,000 shares of DaVita worth $1.97M as of Q4 2014.
  • Adamant Biomedical Investments left its DaVita share count unchanged in Q4 2014.
  • DaVita made up 0.47% of Adamant Biomedical Investments's portfolio in Q4 2014, its #65 holding.
  • Adamant Biomedical Investments first reported a position in DaVita in Q3 2014 and has held it in 2 quarters since.
  • 495 funds tracked by Wall St. Rank held DaVita as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.